Connection

Ali Rizvi to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications Ali Rizvi has written about Diabetes Mellitus, Type 2.
Ali Rizvi
Connection Strength
3.819
Diabetes Mellitus, Type 2
  1. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022 03; 21(3):291-293.
    View in: PubMed
    Score: 0.418
  2. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020 08; 109:154295.
    View in: PubMed
    Score: 0.371
  3. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
    View in: PubMed
    Score: 0.337
  4. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015; 15(10):1391-7.
    View in: PubMed
    Score: 0.264
  5. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opin Pharmacother. 2015 Feb; 16(3):281-4.
    View in: PubMed
    Score: 0.254
  6. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.
    View in: PubMed
    Score: 0.237
  7. Impact of comprehensive diabetes specialty care in the management of older adults with stage 3 or 4 nephropathy. South Med J. 2009 Sep; 102(9):985.
    View in: PubMed
    Score: 0.176
  8. Vitamin D levels in patients seen in the diabetes unit of an academic medical center. South Med J. 2008 Oct; 101(10):1069.
    View in: PubMed
    Score: 0.165
  9. The role of inflammation in diabetes and its complications. South Med J. 2006 Jan; 99(1):8-9.
    View in: PubMed
    Score: 0.136
  10. Type 2 diabetes: epidemiologic trends, evolving pathogenetic [corrected] concepts, and recent changes in therapeutic approach. South Med J. 2004 Nov; 97(11):1079-87.
    View in: PubMed
    Score: 0.126
  11. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Kaunas). 2022 Oct 17; 58(10).
    View in: PubMed
    Score: 0.109
  12. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022 12 01; 1868(12):166559.
    View in: PubMed
    Score: 0.109
  13. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina (Kaunas). 2022 Jan 11; 58(1).
    View in: PubMed
    Score: 0.104
  14. Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. Int J Mol Sci. 2021 Sep 17; 22(18).
    View in: PubMed
    Score: 0.101
  15. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
    View in: PubMed
    Score: 0.101
  16. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2021 08 01; 1867(8):166148.
    View in: PubMed
    Score: 0.098
  17. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
    View in: PubMed
    Score: 0.093
  18. Microvascular and macrovascular effects of liraglutide. Int J Cardiol. 2019 07 01; 286:17-18.
    View in: PubMed
    Score: 0.085
  19. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Res Clin Pract. 2019 Mar; 149:163-169.
    View in: PubMed
    Score: 0.085
  20. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
    View in: PubMed
    Score: 0.080
  21. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
    View in: PubMed
    Score: 0.073
  22. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015 Feb; 100(2):603-6.
    View in: PubMed
    Score: 0.063
  23. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014 Feb 22; 13:49.
    View in: PubMed
    Score: 0.060
  24. Perioperative management of diabetes and hyperglycemia in patients undergoing orthopaedic surgery. J Am Acad Orthop Surg. 2010 Jul; 18(7):426-35.
    View in: PubMed
    Score: 0.047
  25. A collaborative approach to the recruitment and retention of minority patients with diabetes in rural community health centers. Contemp Clin Trials. 2009 Jan; 30(1):63-70.
    View in: PubMed
    Score: 0.041
  26. Recognition and implications of the metabolic syndrome. J S C Med Assoc. 2004 Apr; 100(4):107-12.
    View in: PubMed
    Score: 0.030
  27. Incretins, Pregnancy, and Gestational Diabetes. Curr Pharm Biotechnol. 2016; 17(7):597-602.
    View in: PubMed
    Score: 0.017
  28. A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19(27):4953-63.
    View in: PubMed
    Score: 0.014
  29. Prevalence and impact of initial misclassification of pediatric type 1 diabetes mellitus. South Med J. 2012 Oct; 105(10):513-7.
    View in: PubMed
    Score: 0.014
  30. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 Oct; 18(10):1495-503.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.